Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lucie Ellis

Lucie Ellis, based in the UK, joined the SCRIP Intelligence team in 2012. In her current position as a Creative Content Reporter, she is focused on introducing innovative and imaginative ways to display content on the web and routinely annoys SCRIP’s technology and design teams by thinking too far outside of the box. As a reporter covering the pharma and biotech world, Lucie understandably spends a lot of her time writing about drugs and money or Googling abbreviations. However she has a particular interest in employment trends, social and digital media use by industry, patient-centricity, big data, and clinical research in the metabolic and CNS fields. Lucie enjoys traveling and can often be seen out and about at industry events across the globe as SCRIP’s roving reporter.
Advertisement
Set Alert for Articles By Lucie Ellis

Latest From Lucie Ellis

UCB Promotes 'Underappreciated' Pipeline In FY Results

UCB's pipeline will see advances across multiple therapy areas in 2018, including more emphasis on new epilepsy indications and unmet needs in neurodegenerative diseases like Alzheimer's.  

Business Strategies Sales & Earnings

Preparing Emerging Biotechs For The Best Deals – Insider Insights

As the market for pharma and biotech deal making heats up in 2018, Scrip looks at the process of valuing novel companies with emerging data and collects best advice from experts on how start-ups should pitch to potential pharma partners.

Business Strategies Deals

Exploring Sanofi's Revamped IO Pipeline

In an exclusive interview, Sanofi's head of oncology development Joanne Lager explains how the French big pharma could make a comeback in cancer this year and highlights its immunotherapy combination opportunities.

Business Strategies ImmunoOncology

Santhera Expands Pipeline With Polyphor Cystic Fibrosis Deal

Santhera has moved into cystic fibrosis via a global licensing deal with Polyphor, expanding its rare disease pipeline.

Rare Diseases Deals

M&A Pressure Mounts For Merck & Co After Alzheimer's Drug Dismissed

Merck's verubecestat has flopped in a second Phase III Alzheimer's trial; investors are anticipating M&A or licensing deals soon to bring something new into the big pharma's development portfolio.

Clinical Trials Neurology

J&J Opens First JLABS Site In Europe

Johnson & Johnson Innovation has opened its first JLABS incubator in Europe, the 10th worldwide, with close links to its pharma R&D unit Janssen.

Belgium StartUps and SMEs
See All
Advertisement
UsernamePublicRestriction

Register